The world market for melanoma therapeutics is projected to reach $1.1 billion by 2015.
This is primarily driven by rapid rise in the number of people suffering from melanoma of skin, due to increased exposure to UV rays and depletion of ozone layer.
The United States dominates the world melanoma therapeutics market as stated by the new market research report on Melanoma Therapeutics market. Melanoma represents the most lethal form of skin cancers in the US.
Incidence of melanoma has almost doubled during the past thirty years, and is increasing continually, claiming the life of one individual every hour.
Melanoma cancer market presents immense commercial opportunities for drug developers, specifically to address unmet medical needs in metastatic condition.
Key players profiled in the report include Abraxis BioScience Inc., Astellas Pharma US Inc., Antigenics Inc., AVAX Technologies Inc., BioVex Inc., GenVec Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Vical, Inc.